Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib + Ramucirumab for Stomach or Esophageal Cancer
Recruiting1 awardPhase 1 & 2
Guilford, Connecticut
This trial is testing olaparib + ramucirumab to treat gastric/gastroesophageal junction cancer that has spread or come back.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.